Genelux Corporation
GNLX Healthcare Biotechnology
Genelux Corporation’s revenue for fiscal 2025 (year ended December 2025) was $8,000.00, roughly unchanged from fiscal 2024. In the quarter to June 2026, EPS fell 5.00% and free cash flow fell 11.2%, each against the same quarter a year earlier.
Follow GNLX
Genelux Corporation (GNLX) EV/Sales
As of 16 October 2026, Genelux Corporation (GNLX) trades at a EV/Sales of 8.8×. Over the past ten years it has ranged from 0.0× (March 2024) to 26.7× (November 2025); the current reading is higher than 68% of that period. That is in line with the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 13.9× | 200.89% |
| FY2024 | 4.6× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2024 | 11.5× | — |
| Mar 2023 | 0.0× | — |
| Dec 2022 | 0.0× | — |
| Sep 2022 | 0.0× | — |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LENZ LENZ Therapeutics, Inc. compare | −5.4× |
| SEER Seer, Inc. compare | −2.9× |
| TNXP Tonix Pharmaceuticals Holding Corp. compare | −2.3× |
| FHTX Foghorn Therapeutics Inc. compare | −0.5× |
| ENGN enGene Therapeutics Inc compare | n/m |
| NERV Minerva Neurosciences, Inc compare | n/m |
| VTVT vTv Therapeutics Inc. compare | 6.5× |
| GNLX Genelux Corporation | 8.8× |
| ARMP Armata Pharmaceuticals, Inc. compare | 68.8× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)